Coronavirus simulations completed on supercomputer
Biochemist leads simulations to help design new drugs, vaccines to combat coronavirus More at https://www.nsf.gov/discoveries/disc_summ.jsp?cntn_id=300313&WT.mc_id=USNSF_1 This is a Research News item.
The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose vaccine trial participants to the pathogen, but it may become an option if ongoing trials hit a snag.Reuters Health Information
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
by Jamie Webb MA, MSci ‘An experimental vaccine against the coronavirus showed encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers, its maker announced Monday.’ Readers of the Associated Press’s lead paragraph on Moderna’s vaccine candidate for COVID-19 could be forgiven for getting excited. However, the same article ends with this caveat, “The results have not been published and are only from the first of three stages of testing that vaccines and drugs normally undergo.” Rather than published data, the...
CONCLUSIONS: This new disease is pushing the scientific community to develop swiftly a safe and effective vaccine. Notwithstanding the limitations of our analysis, given by the absence of available results, we try to provide a comprehensive view of the ongoing clinical trials in humans. Our analysis reveals a worldwide effort of both scientists and enterprises to achieve one of the most challenging goals of our century. PMID: 32456404 [PubMed - as supplied by publisher]
Small animal models (mice, ferrets, hamsters) are essential for understanding how SARS-CoV-2 causes disease and for pre-clinical evaluation of vaccines and antiviral therapeutics. One promising model has been developed by modifying SARS-CoV-2 so that it binds to murine ACE2. Laboratory mice cannot be infected with SARS-CoV-2 because the viral spike glycoprotein (illustrated) does not bind […]
NPR's science correspondent answers listener questions about the pace and process needed to develop a viable coronavirus vaccine.
New research suggests that 6-feet of social distancing may not be enough to prevent the coronavirus. There is also a shortage of glass vials that may slow down the production of the vaccine as coronavirus cases continue to increase in America. Omar Villafranca reports.
These are the coronavirus stories you need to know about today.Medscape Medical News
(Natural News) Are Americans losing essential freedoms in the midst of the coronavirus crisis? In an interview with Charlene Bollinger from “The Truth About Vaccines 2020”, Richard Mack, political activist and former Arizona sheriff, spoke about the Constitution, liberty and freedom in light of coronavirus and connected the current situation to his victory in a...
As the global prevalence of novel coronavirus 2019 (COVID-19) increases, with a death toll exceeding that during wartime, scientists and clinicians alike are racing against time to provide clarity on pathogenesis, mode of transmission, and to research potential treatment and vaccines amid the pandemic. In the meantime, hospital guidance1 is essential to protect health care providers (HCPs) and for disease containment. However, definitive guidelines are often elusive given the rapid emergence of new data and the time constraints for robust evidence.